Personalis, Inc. (FRA:04X)

Germany · Delayed Price · Currency is EUR

9.03

+0.30 (3.50%)

Last updated: Dec 5, 2025, 9:50 AM CET

148.90% (1Y)

Market Cap	798.05M
Revenue (ttm)	58.90M
Net Income (ttm)	-62.97M
Shares Out	n/a
EPS (ttm)	-0.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	256
Open	9.02
Previous Close	8.72
Day's Range	9.02 - 9.03
52-Week Range	2.56 - 9.57
Beta	n/a
RSI	56.80
Earnings Date	Feb 27, 2026

About Personalis

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances

Founded 2011

Employees 229

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 04X

Full Company Profile

Financial Performance

In 2024, Personalis's revenue was $84.61 million, an increase of 15.15% compared to the previous year's $73.48 million. Losses were -$81.28 million, -24.94% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.